The Challenges of Developing an Antiviral Agent for the Treatment of Smallpox Using the Animal Efficacy Rule
Authors:
- 1 March 2006
- journal article
- Published by Taylor & Francis in Future Virology
- Vol. 1 (2) , 173-179
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpoxProceedings of the National Academy of Sciences, 2004
- The host response to smallpox: Analysis of the gene expression program in peripheral blood cells in a nonhuman primate modelProceedings of the National Academy of Sciences, 2004
- Design and development of oral drugs for the prophylaxis and treatment of smallpox infectionTrends in Biotechnology, 2004
- Oral Treatment of Cowpox and Vaccinia Virus Infections in Mice with Ether Lipid Esters of CidofovirAntimicrobial Agents and Chemotherapy, 2004
- Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox modelVirology, 2004
- Efficacy of Multiple- or Single-Dose Cidofovir against Vaccinia and Cowpox Virus Infections in MiceAntimicrobial Agents and Chemotherapy, 2003
- Developing New Smallpox VaccinesEmerging Infectious Diseases, 2001
- Creation of Killer Poxvirus Could Have Been PredictedJournal of Virology, 2001
- Expression of Mouse Interleukin-4 by a Recombinant Ectromelia Virus Suppresses Cytolytic Lymphocyte Responses and Overcomes Genetic Resistance to MousepoxJournal of Virology, 2001
- Smallpox as a Biological WeaponJAMA, 1999